Chen Lin, Xie Yuxin, Yu Min, Gou Qiheng
Department of Head and Neck Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People's Republic of China.
Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People's Republic of China.
Cancer Manag Res. 2022 May 21;14:1771-1782. doi: 10.2147/CMAR.S365762. eCollection 2022.
There is an urgent need to identify reliable biomarkers that can be used in early diagnosis, prognostication prediction and as possible therapeutic targets for lung cancer due to its current poor prognosis. Long noncoding RNAs (lncRNAs) have recently attracted additional attention due to their potential role in carcinogenesis, invasion and metastasis. Issues involved in the biofunctions and regulatory mechanisms of oncogenic and tumor-suppressive lncRNAs in lung cancer are discussed. Some lncRNAs have shown good diagnostic value, especially in combination with conventional serum protein markers. The use of antisense oligonucleotides, small molecules and RNA interference techniques have shown promise as direct therapeutic tools for targeting lncRNAs in preclinical studies. The biomarker function of lncRNAs may also indirectly involved in tumor therapy as a reference to conventional therapy. Overall, the concept of using lncRNAs as biomarkers for prognostication and intervention in lung cancer is still in its infancy, and only with more in-depth studies could they have a significant impact.
由于目前肺癌预后较差，迫切需要鉴定出可用于早期诊断、预后预测并作为可能的治疗靶点的可靠生物标志物。长链非编码RNA（lncRNAs）最近因其在致癌、侵袭和转移中的潜在作用而受到更多关注。本文讨论了肺癌中致癌和抑癌lncRNAs的生物学功能和调控机制所涉及的问题。一些lncRNAs已显示出良好的诊断价值，尤其是与传统血清蛋白标志物联合使用时。在临床前研究中，反义寡核苷酸、小分子和RNA干扰技术作为靶向lncRNAs的直接治疗工具已显示出前景。lncRNAs的生物标志物功能也可能作为传统治疗的参考而间接参与肿瘤治疗。总体而言，将lncRNAs用作肺癌预后评估和干预生物标志物的概念仍处于起步阶段，只有通过更深入的研究，它们才能产生重大影响。
